
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8639870/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 2007, 447, 661-678.	27.8	8,895
2	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 2677-2686.	6.7	3,838
3	Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nature Genetics, 2007, 39, 1329-1337.	21.4	1,298
4	Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature, 2010, 464, 713-720.	27.8	737
5	Trial of Anifrolumab in Active Systemic Lupus Erythematosus. New England Journal of Medicine, 2020, 382, 211-221.	27.0	725
6	EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Annals of the Rheumatic Diseases, 2010, 69, 2074-2082.	0.9	578
7	A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease Loci. PLoS Genetics, 2008, 4, e1000041.	3.5	572
8	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Annals of the Rheumatic Diseases, 2014, 73, 958-967.	0.9	558
9	Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature, 2007, 450, 887-892.	27.8	493
10	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet, The, 2018, 392, 222-231.	13.7	396
11	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2015, 74, 1706-1713.	0.9	391
12	The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology, 2016, 55, 252-262.	1.9	370
13	Rheumatoid arthritis association at 6q23. Nature Genetics, 2007, 39, 1431-1433.	21.4	361
14	Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nature Genetics, 2010, 42, 996-999.	21.4	334
15	Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. Arthritis and Rheumatism, 2003, 48, 3159-3167.	6.7	327
16	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561.	0.9	268
17	Association between thePTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: Further support thatPTPN22 is an autoimmunity gene. Arthritis and Rheumatism, 2005, 52, 1694-1699.	6.7	266
18	Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study. Arthritis and Rheumatism, 2007, 56, 265-273.	6.7	262

#	Article	IF	CITATIONS
19	Development and validation of a diseaseâ€specific healthâ€related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 57, 972-979.	6.7	252
20	Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatology, The, 2019, 1, e208-e219.	3.9	250
21	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology, 2018, 57, e1-e45.	1.9	247
22	â€~Not only…but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology, 2005, 44, 1492-1502.	1.9	244
23	Systemic Lupus Erythematosus. Circulation, 2004, 110, 399-404.	1.6	242
24	Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2010, 69, 529-535.	0.9	240
25	Atherosclerosis in rheumatoid arthritis: is it all about inflammation?. Nature Reviews Rheumatology, 2015, 11, 390-400.	8.0	221
26	Drug-Induced Interstitial Lung Disease: A Systematic Review. Journal of Clinical Medicine, 2018, 7, 356.	2.4	215
27	Clinical applications of machine learning algorithms: beyond the black box. BMJ: British Medical Journal, 2019, 364, 1886.	2.3	213
28	The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology, 2011, 50, 982-988.	1.9	155
29	PREMATURE ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS. Rheumatic Disease Clinics of North America, 2000, 26, 257-278.	1.9	154
30	Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care and Research, 2010, 62, 881-887.	3.4	153
31	Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. Annals of the Rheumatic Diseases, 2007, 67, 672-676.	0.9	149
32	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nature Communications, 2015, 6, 6046.	12.8	149
33	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Annals of the Rheumatic Diseases, 2012, 71, 1502-1509.	0.9	143
34	Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2011, 70, 1726-1732.	0.9	132
35	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2022, 81, 768-779.	0.9	128
36	Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care and Research, 2012, 64, 132-137.	3.4	126

#	Article	IF	CITATIONS
37	Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis and Rheumatism, 2008, 58, 3705-3709.	6.7	122
38	The Systemic Lupus International Collaborating Clinics (SLICC) damage index: A systematic literature review. Seminars in Arthritis and Rheumatism, 2013, 43, 352-361.	3.4	118
39	Numerical scoring for the BILAG-2004 index. Rheumatology, 2010, 49, 1665-1669.	1.9	111
40	Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. Journal of Clinical Pharmacy and Therapeutics, 2007, 32, 187-195.	1.5	109
41	Anti-C1q antibodies in systemic lupus erythematosus. Lupus, 2015, 24, 42-49.	1.6	106
42	Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Annals of the Rheumatic Diseases, 2011, 70, 1641-1644.	0.9	103
43	Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology, 2012, 51, 634-643.	1.9	102
44	The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Evidence of an ethnic gradient. Arthritis and Rheumatism, 2006, 54, 2963-2969.	6.7	101
45	Factors associated with fatigue in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 1999, 58, 379-381.	0.9	99
46	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2015, 67, 1837-1847.	5.6	98
47	2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science and Medicine, 2021, 8, e000538.	2.7	97
48	British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 56, 4113-4119.	6.7	96
49	Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity. Lupus, 2011, 20, 250-255.	1.6	96
50	Revised British Isles Lupus Assessment Group 2004 index: A reliable tool for assessment of systemic lupus erythematosus activity. Arthritis and Rheumatism, 2006, 54, 3300-3305.	6.7	93
51	Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Annals of the Rheumatic Diseases, 2007, 67, 677-682.	0.9	92
52	Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics Journal, 2013, 13, 227-234.	2.0	91
53	The BILAC-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology, 2009, 48, 691-695.	1.9	90
54	Modifiable risk factors for RA: prevention, better than cure?. Rheumatology, 2012, 51, 499-512.	1.9	90

IAN N BRUCE

#	Article	lF	CITATIONS
55	Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. Journal of Rheumatology, 2006, 33, 50-6.	2.0	89
56	Prolonged remission in systemic lupus erythematosus. Journal of Rheumatology, 2005, 32, 1467-72.	2.0	87
57	An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Annals of the Rheumatic Diseases, 2011, 70, 54-59.	0.9	86
58	Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus, 2007, 16, 731-735.	1.6	85
59	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. Arthritis and Rheumatism, 2013, 65, 2887-2897.	6.7	84
60	Risk Factors for Clinical Coronary Heart Disease in Systemic Lupus Erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) Study. Journal of Rheumatology, 2010, 37, 322-329.	2.0	83
61	Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus, 2016, 25, 699-709.	1.6	82
62	Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open, 2019, 9, e025687.	1.9	81
63	Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis. Annals of the Rheumatic Diseases, 2002, 61, 1007-1011.	0.9	78
64	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2013, 72, 1308-1314.	0.9	78
65	25-Hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus. Rheumatology, 2012, 51, 544-551.	1.9	77
66	Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. Trials, 2019, 20, 429.	1.6	77
67	A Multicenter, Randomized, Placebo ontrolled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2019, 71, 1437-1449.	5.6	77
68	Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2014, 73, 1144-1150.	0.9	75
69	Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results) Tj ETQq1 1 0.7	84314 rgB ⁻ 0.9	T /Overlock 1 75
70	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology, 2018, 57, 470-479.	1.9	73
71	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2015, 74, 1530-1536.	0.9	70
72	Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	3.4	70

#	Article	IF	CITATIONS
73	A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics, 2011, 12, 815-826.	1.3	69
74	The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. Rheumatology, 2015, 54, 1780-1791.	1.9	69
75	Evidence to support <i>IL-13</i> as a risk locus for psoriatic arthritis but not psoriasis vulgaris. Annals of the Rheumatic Diseases, 2011, 70, 1016-1019.	0.9	68
76	MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. Pharmacogenomics Journal, 2013, 13, 137-147.	2.0	67
77	Systemic lupus international collaborating clinics renal activity/response exercise: Development of a renal activity score and renal response index. Arthritis and Rheumatism, 2008, 58, 1784-1788.	6.7	66
78	Successful Intravenous Immunoglobulin Therapy in 3 Cases of Parvovirus B19–Associated Chronic Fatigue Syndrome. Clinical Infectious Diseases, 2003, 36, e100-e106.	5.8	65
79	Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis and Rheumatism, 2005, 52, 3596-3602.	6.7	65
80	HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis. Annals of the Rheumatic Diseases, 2007, 66, 807-811.	0.9	64
81	PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. Annals of the Rheumatic Diseases, 2015, 74, 1882-1885.	0.9	64
82	Variants in <i>RUNX3</i> Contribute to Susceptibility to Psoriatic Arthritis, Exhibiting Further Common Ground With Ankylosing Spondylitis. Arthritis and Rheumatism, 2013, 65, 1224-1231.	6.7	63
83	Indications for IVIG in rheumatic diseases. Rheumatology, 2015, 54, 383-391.	1.9	63
84	The effect of probucol and vitamin E treatment on the oxidation of low-density lipoprotein and forearm vascular responses in humans. European Journal of Clinical Investigation, 1994, 24, 759-765.	3.4	62
85	High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus, 2007, 16, 387-393.	1.6	62
86	Lupus community panel proposals for optimising clinical trials: 2018. Lupus Science and Medicine, 2018, 5, e000258.	2.7	62
87	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence. Arthritis and Rheumatism, 2000, 13, 406-408.	6.7	56
88	Cardiovascular disease in lupus patients: Should all patients be treated with statins and aspirin?. Best Practice and Research in Clinical Rheumatology, 2005, 19, 823-838.	3.3	56
89	The influence of age at symptom onset and length of followup on mortality in patients with recentâ€onset inflammatory polyarthritis. Arthritis and Rheumatism, 2008, 58, 985-989.	6.7	56
90	Therapy Insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 423-430.	3.3	55

#	Article	IF	CITATIONS
91	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care and Research, 2018, 70, 1478-1487.	3.4	55
92	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2019, 71, 281-289.	5.6	55
93	The LupusQoL and Associations with Demographics and Clinical Measurements in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2010, 37, 2273-2279.	2.0	54
94	Vitamin D improves endothelial dysfunction and restores myeloid angiogenic cell function via reduced CXCL-10 expression in systemic lupus erythematosus. Scientific Reports, 2016, 6, 22341.	3.3	54
95	The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus, 2017, 26, 1051-1059.	1.6	52
96	Vitamin D and systemic lupus erythematosus - The hype and the hope. Autoimmunity Reviews, 2018, 17, 19-23.	5.8	52
97	Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. Lupus Science and Medicine, 2016, 3, e000143.	2.7	50
98	Altered cognitive function in systemic lupus erythematosus and associations with inflammation and functional and structural brain changes. Annals of the Rheumatic Diseases, 2019, 78, 934-940.	0.9	50
99	BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000. Annals of the Rheumatic Diseases, 2008, 67, 873-876.	0.9	49
100	25â€Hydroxyvitamin D and Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Data From a Large International Inception Cohort. Arthritis Care and Research, 2014, 66, 1167-1176.	3.4	49
101	Individuals living with lupus: findings from the LUPUS UK Members Survey 2014. Lupus, 2018, 27, 681-687.	1.6	49
102	Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology, 2021, 60, 5397-5407.	1.9	48
103	Tartrateâ€Resistant Acid Phosphatase Deficiency in the Predisposition to Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2017, 69, 131-142.	5.6	47
104	SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2011, 70, 961-967.	0.9	45
105	Changes in Quality of Life in the First 5 Years of Disease in a Multicenter Cohort of Patients With Systemic Lupus Erythematosus. Arthritis Care and Research, 2014, 66, 1374-1379.	3.4	45
106	Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus. Arthritis Care and Research, 2016, 68, 1505-1513.	3.4	45
107	A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. Rheumatology, 2016, 55, 382-384.	1.9	45
108	Hyperuricemia in Psoriatic Arthritis. Journal of Clinical Rheumatology, 2000, 6, 6-9.	0.9	44

#	Article	IF	CITATIONS
109	Atherogenesis and autoimmune disease: the model of lupus. Lupus, 2005, 14, 687-690.	1.6	43
110	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. Rheumatology, 2018, 57, 14-18.	1.9	43
111	An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus. Lupus, 2011, 20, 1459-1465.	1.6	42
112	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 2022, 81, 370-378.	0.9	42
113	Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations. Arthritis Research and Therapy, 2018, 20, 173.	3.5	41
114	Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2003, 62, 15-19.	0.9	40
115	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. Arthritis and Rheumatology, 2016, 68, 1932-1944.	5.6	40
116	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Annals of the Rheumatic Diseases, 2020, 79, 356-362.	0.9	40
117	Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort. Annals of the Rheumatic Diseases, 2012, 71, 1350-1354.	0.9	39
118	Electrocardiographic Findings in Systemic Lupus Erythematosus: Data From an International Inception Cohort. Arthritis Care and Research, 2015, 67, 128-135.	3.4	39
119	Current challenges in the development of new treatments for lupus. Annals of the Rheumatic Diseases, 2019, 78, 729-735.	0.9	39
120	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2020, 72, 67-77.	5.6	39
121	Brief Report: Shortened Telomere Length in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatism, 2013, 65, 1319-1323.	6.7	38
122	Contribution of rare and predicted pathogenic gene variants to childhood-onset lupus: a large, genetic panel analysis of British and French cohorts. Lancet Rheumatology, The, 2020, 2, e99-e109.	3.9	38
123	Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Annals of the Rheumatic Diseases, 2022, 81, 951-961.	0.9	38
124	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology, 2018, 57, 677-687.	1.9	37
125	Digital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud's phenomenon. Annals of the Rheumatic Diseases, 2000, 59, 870-874.	0.9	36
126	Myocardial Perfusion Imaging in Assessing Risk of Coronary Events in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2009, 36, 288-294.	2.0	36

#	Article	IF	CITATIONS
127	Variants in linkage disequilibrium with the late cornified envelope gene cluster deletion are associated with susceptibility to psoriatic arthritis. Annals of the Rheumatic Diseases, 2010, 69, 2199-2203.	0.9	36
128	The role of antirheumatics in patients with COVID-19. Lancet Rheumatology, The, 2021, 3, e447-e459.	3.9	36
129	Numerical scoring for the Classic BILAG index. Rheumatology, 2009, 48, 1548-1552.	1.9	35
130	Atherosclerosis and systemic lupus erythematosus. Current Rheumatology Reports, 2000, 2, 19-23.	4.7	34
131	Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Current Opinion in Lipidology, 2008, 19, 338-343.	2.7	34
132	Decreased live births in women with systemic lupus erythematosus. Arthritis Care and Research, 2011, 63, 1068-1072.	3.4	34
133	Microparticle subpopulations are potential markers of disease progression and vascular dysfunction across a spectrum of connective tissue disease. BBA Clinical, 2017, 7, 16-22.	4.1	34
134	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. Journal of Rheumatology, 2020, 47, 72-81.	2.0	34
135	Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. Lancet Rheumatology, The, 2022, 4, e282-e292.	3.9	34
136	Biomarkers of oxidant stress, insulin sensitivity and endothelial activation in rheumatoid arthritis: a cross-sectional study of their association with accelerated atherosclerosis. BMC Research Notes, 2009, 2, 83.	1.4	32
137	SLE and pregnancy: the potential role for regulatory T cells. Nature Reviews Rheumatology, 2011, 7, 124-128.	8.0	32
138	Activation of transforming growth factor-beta1 and early atherosclerosis in systemic lupus erythematosus. Arthritis Research and Therapy, 2006, 8, R81.	3.5	31
139	The Metabolic Syndrome in Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America, 2010, 36, 81-97.	1.9	31
140	N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR). Annals of the Rheumatic Diseases, 2014, 73, 684-690.	0.9	31
141	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Science and Medicine, 2021, 8, e000590.	2.7	31
142	Reduction of longâ€ŧerm disability in inflammatory polyarthritis by early and persistent suppression of joint inflammation: Results from the Norfolk Arthritis Register. Arthritis Care and Research, 2011, 63, 945-952.	3.4	30
143	Brief Report: Vitamin D Deficiency Is Associated With Endothelial Dysfunction and Increases Type I Interferon Gene Expression in a Murine Model of Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2016, 68, 2929-2935.	5.6	30
144	Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. II. Predictive factors for perfusion abnormalities. Journal of Rheumatology, 2003, 30, 288-91.	2.0	30

IAN N BRUCE

#	Article	IF	CITATIONS
145	Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. RMD Open, 2017, 3, e000314.	3.8	29
146	Rheumatoid arthritis reprograms circadian output pathways. Arthritis Research and Therapy, 2019, 21, 47.	3.5	29
147	Golimumab for the Treatment of Psoriatic Arthritis. Pharmacoeconomics, 2012, 30, 257-270.	3.3	28
148	American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort. Journal of Rheumatology, 2014, 41, 875-880.	2.0	28
149	Cognitive dysfunction and functional magnetic resonance imaging in systemic lupus erythematosus. Lupus, 2015, 24, 1239-1247.	1.6	28
150	Cell adhesion molecules as potential biomarkers of nephritis, damage and accelerated atherosclerosis in patients with SLE. Lupus, 2014, 23, 819-824.	1.6	27
151	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity, 2020, 106, 102340.	6.5	27
152	Seropositivity is associated with insulin resistance in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register (NOAR): an observational study. Arthritis Research and Therapy, 2011, 13, R159.	3.5	26
153	Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients. Arthritis Care and Research, 2018, 70, 98-103.	3.4	26
154	Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor–treated rheumatoid arthritis patients. Rheumatology, 2019, 58, 2162-2169.	1.9	26
155	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis and Rheumatology, 2020, 72, 658-666.	5.6	26
156	A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment. Rheumatology, 2021, 60, 3747-3759.	1.9	26
157	Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey. Lupus Science and Medicine, 2017, 4, e000173.	2.7	25
158	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1297-1307.	5.6	25
159	Regulatory <scp>T</scp> cells in Systemic Lupus Erythematosus and Pregnancy. American Journal of Reproductive Immunology, 2013, 69, 588-595.	1.2	24
160	The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease. Lupus, 2014, 23, 273-283.	1.6	23
161	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2020, 72, 1800-1808.	3.4	23
162	An audit of ANCA in routine clinical practice. Postgraduate Medical Journal, 1995, 71, 605-612.	1.8	22

#	Article	IF	CITATIONS
163	Vitamin D treatment for connective tissue diseases: hope beyond the hype?. Rheumatology, 2017, 56, 178-186.	1.9	22
164	QRISK3 improves detection of cardiovascular disease risk in patients with systemic lupus erythematosus. Lupus Science and Medicine, 2018, 5, e000272.	2.7	22
165	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. Arthritis Care and Research, 2021, 73, 1231-1235.	3.4	22
166	Association between age at disease onset of anti-neutrophil cytoplasmic antibody–associated vasculitis and clinical presentation and short-term outcomes. Rheumatology, 2021, 60, 617-628.	1.9	22
167	Re-evaluation of biologic therapies in systemic lupus erythematosus. Current Opinion in Rheumatology, 2010, 22, 273-277.	4.3	21
168	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2018, 70, 1294-1302.	3.4	21
169	Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment. RMD Open, 2020, 6, e001257.	3.8	21
170	Genetic epidemiology: systemic lupus erythematosus. Arthritis Research, 2001, 3, 331.	2.0	20
171	Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug. Annals of the Rheumatic Diseases, 2006, 65, 1390-1393.	0.9	20
172	Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review. Seminars in Arthritis and Rheumatism, 2017, 47, 384-396.	3.4	20
173	Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles. Arthritis Research and Therapy, 2019, 21, 147.	3.5	20
174	Cardiovascular risk factors in inflammatory arthritis. Current Opinion in Lipidology, 2011, 22, 296-301.	2.7	19
175	Association of morbid obesity with disability in early inflammatory polyarthritis: Results from the Norfolk Arthritis Register. Arthritis Care and Research, 2013, 65, 122-126.	3.4	19
176	Improving cardiovascular outcomes in rheumatic diseases: Therapeutic potential of circulating endothelial progenitor cells. , 2014, 142, 231-243.		19
177	Progression of subclinical and clinical cardiovascular disease in a UK SLE cohort: the role of classic and SLE-related factors. Lupus Science and Medicine, 2018, 5, e000267.	2.7	19
178	Differential analysis of serum and urine S100 proteins in juvenile-onset systemic lupus erythematosus (jSLE). Clinical Immunology, 2020, 214, 108375.	3.2	19
179	Systemic lupus erythematosus, eosinophilic vasculitis and acalculous cholecystitis. Nephrology Dialysis Transplantation, 2006, 21, 792-795.	0.7	18
180	Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. Lupus Science and Medicine, 2022, 9, e000634.	2.7	18

#	Article	IF	CITATIONS
181	Health-related quality of life, smoking and carotid atherosclerosis in white British women with systemic lupus erythematosus. Lupus, 2010, 19, 231-238.	1.6	17
182	Clinical trials in lupus: what have we learned so far?. Rheumatology, 2010, 49, 1025-1027.	1.9	17
183	Construct and Criterion Validity of the Short Form-6D Utility Measure in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2012, 39, 735-742.	2.0	17
184	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis and Rheumatology, 2020, 72, 1734-1740.	5.6	17
185	Endothelial progenitor cells: a new player in lupus?. Arthritis Research and Therapy, 2012, 14, 203.	3.5	16
186	Evaluation of carotid plaque inflammation in patients with active rheumatoid arthritis using 18F-fluorodeoxyglucose PET-CT and MRI: a pilot study. Lancet, The, 2015, 385, S91.	13.7	16
187	Psoriatic Arthritis. BioDrugs, 1998, 9, 271-278.	4.6	15
188	Systemic lupus international collaborating clinics renal activity/response exercise: Comparison of agreement in rating renal response. Arthritis and Rheumatism, 2008, 58, 1789-1795.	6.7	15
189	Systemic lupus erythematosus, regulatory T cells and pregnancy. Expert Review of Clinical Immunology, 2011, 7, 635-648.	3.0	15
190	Investigation ofIL1,VEGF,PPARGandMEFVgenes in psoriatic arthritis susceptibility: Table 1. Annals of the Rheumatic Diseases, 2012, 71, 313-314.	0.9	15
191	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. Journal of Rheumatology, 2019, 46, 492-500.	2.0	15
192	Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project. Lupus Science and Medicine, 2019, 6, e000342.	2.7	15
193	Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Annals of the Rheumatic Diseases, 2022, 81, 962-969.	0.9	15
194	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. Rheumatology, 2021, 60, 4737-4747.	1.9	14
195	Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index. Rheumatology, 2022, 61, 4006-4015.	1.9	14
196	Certolizumab pegol attenuates the pro-inflammatory state in endothelial cells in a manner that is atheroprotective. Clinical and Experimental Rheumatology, 2013, 31, 225-33.	0.8	14
197	Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. Journal of Comparative Effectiveness Research, 2022, 11, 765-777.	1.4	14
198	Risk factors for coronary heart disease in connective tissue diseases. Therapeutic Advances in Musculoskeletal Disease, 2010, 2, 145-153.	2.7	13

IAN N BRUCE

#	Article	IF	CITATIONS
199	The BILAG-2004 systems tally—a novel way of representing the BILAG-2004 index scores longitudinally. Rheumatology, 2012, 51, 2099-2105.	1.9	13
200	Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales. Clinical Rheumatology, 2012, 31, 1005-1012.	2.2	13
201	Cardiovascular risk and inflammatory rheumatic diseases. Clinical Medicine, 2013, 13, 395-397.	1.9	13
202	Cardiovascular risk and its modification in patients with connective tissue diseases. Best Practice and Research in Clinical Rheumatology, 2016, 30, 81-94.	3.3	12
203	Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply. Rheumatology, 2018, 57, 1502-1503.	1.9	12
204	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Annals of the Rheumatic Diseases, 2019, 78, 1010-1012.	0.9	12
205	What Does it Mean to be a British Isles Lupus Assessment Group–Based Composite Lupus Assessment Responder? Post Hoc Analysis of 2 Phase 3 Trials. Arthritis and Rheumatology, 2021, 73, 2059-2068.	5.6	12
206	Differential levels of IFNÎ \pm subtypes in autoimmunity and viral infection. Cytokine, 2021, 144, 155533.	3.2	12
207	The Effect of Type 1 IFN on Human Aortic Endothelial Cell Function <i>In Vitro</i> : Relevance to Systemic Lupus Erythematosus. Journal of Interferon and Cytokine Research, 2014, 34, 404-412.	1.2	11
208	Mapping the disease-specific LupusQoL to the SF-6D. Quality of Life Research, 2015, 24, 1749-1758.	3.1	11
209	Drug efflux transporters in rheumatoid arthritis: Comment on the article by Kremer. Arthritis and Rheumatism, 2005, 52, 670-670.	6.7	10
210	Evolving concepts in systemic lupus erythematosus damage assessment. Nature Reviews Rheumatology, 2021, 17, 307-308.	8.0	10
211	Subclinical atherosclerosis in systemic lupus erythematosus. Journal of Rheumatology, 2004, 31, 841-3.	2.0	10
212	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€FI). Arthritis Care and Research, 2020, , .	3.4	9
213	The challenges in data integration – heterogeneity and complexity in clinical trials and patient registries of Systemic Lupus Erythematosus. BMC Medical Research Methodology, 2020, 20, 164.	3.1	9
214	Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Rheumatology, The, 2021, 3, e101-e110.	3.9	9
215	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2022, 81, 1143-1150.	0.9	9
216	Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2022, 74, 1822-1828.	3.4	9

#	Article	IF	CITATIONS
217	Improved wrist pannus volume measurement from contrast-enhanced MRI in rheumatoid arthritis using shuffle transform. Magnetic Resonance Imaging, 2007, 25, 110-116.	1.8	8
218	Cardiovascular Outcomes in Systemic Lupus Erythematosus: Big Studies for Big Questions. Journal of Rheumatology, 2009, 36, 467-469.	2.0	8
219	Can we identify who gets benefit or harm from mycophenolate mofetil in systemic lupus erythematosus? A systematic review. Seminars in Arthritis and Rheumatism, 2017, 47, 65-78.	3.4	8
220	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology, 2019, 58, 1259-1267.	1.9	8
221	Estimation of the burden of shielding among a cross-section of patients attending rheumatology clinics with SLE—data from the BSR audit of systemic lupus erythematosus. Rheumatology, 2021, 60, 1474-1479.	1.9	8
222	The effects of disease activity on neuronal and behavioural cognitive processes in systemic lupus erythematosus. Rheumatology, 2021, 61, 195-204.	1.9	8
223	Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR). Lupus Science and Medicine, 2021, 8, e000513.	2.7	8
224	Clinical Markers, Metrics, Indices, and Clinical Trials. , 2019, , 614-630.		7
225	BSR guideline on the management of adults with systemic lupus erythematosus (SLE) 2018: baseline multi-centre audit in the UK. Rheumatology, 2021, 60, 1480-1490.	1.9	7
226	Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme. Lupus Science and Medicine, 2021, 8, e000459.	2.7	7
227	The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research. Lupus Science and Medicine, 2021, 8, e000433.	2.7	7
228	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. Arthritis and Rheumatology, 2021, 73, 2293-2302.	5.6	7
229	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2023, 75, 998-1006.	3.4	7
230	Translating research into clinical practice: quality improvement to halve non-adherence to methotrexate. Rheumatology, 2021, 60, 125-131.	1.9	6
231	Demographic and disease-related predictors of abnormal lung function in patients with established inflammatory polyarthritis and a comparison with the general population. Annals of the Rheumatic Diseases, 2013, 72, 1517-1523.	0.9	5
232	Generating evidence to inform health technology assessment of treatments for SLE: a systematic review of decision-analytic model-based economic evaluations. Lupus Science and Medicine, 2020, 7, e000350.	2.7	5
233	Flares in patients with systemic lupus erythematosus. Rheumatology, 2021, 60, 3262-3267.	1.9	5
234	Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the PRe-clinical EValuation of Novel Targets in RA (PREVeNT-RA) Cohort. Arthritis Research and Therapy, 2021, 23, 210.	3.5	5

#	Article	IF	CITATIONS
235	Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial. Lupus Science and Medicine, 2022, 9, e000584.	2.7	5
236	Accelerated atherosclerosis and cardiovascular disease in systemic lupus erythematosus. Revista Colombiana De ReumatologÃa, 2021, 28, 21-30.	0.1	4
237	Longitudinal analysis of urinary proteins in lupus nephritis – A pilot study. Clinical Immunology, 2022, 236, 108948.	3.2	4
238	Evaluation of non-contrast MRI biomarkers in lupus nephritis. Clinical and Experimental Rheumatology, 2017, 35, 954-958.	0.8	4
239	Coronary heart disease (CHD) in lupus: round up the usual suspects?. Lupus, 2004, 13, 557-560.	1.6	3
240	136 Motor and cognitive fatigue in SLE is associated with mood and health-related quality of life (HRQoL) in patients with SLE: results from the Patient Reported Outcomes in Lupus (PRO-Lupus) study. Rheumatology, 2018, 57, .	1.9	3
241	Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians. Lancet Rheumatology, The, 2020, 2, e735-e736.	3.9	3
242	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. Lupus, 2021, 30, 096120332110142.	1.6	3
243	Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory models. Arthritis Research and Therapy, 2021, 23, 203.	3.5	3
244	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence. Arthritis and Rheumatism, 2000, 13, 406-408.	6.7	3
245	The effects of disease activity, inflammation, depression and cognitive fatigue on resting state fMRI in systemic lupus erythematosus. Rheumatology, 2022, 61, SI39-SI47.	1.9	3
246	Immune gene expression and functional networks in distinct lupus nephritis classes. Lupus Science and Medicine, 2022, 9, e000615.	2.7	3
247	Investigation of association of the DLG5 gene with psoriatic arthritis. Annals of the Rheumatic Diseases, 2006, 66, 273-274.	0.9	2
248	Vitamin D in systemic lupus erythematosus: potential beyond bone health. International Journal of Clinical Rheumatology, 2009, 4, 297-309.	0.3	2
249	The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. Rheumatology, 2017, 56, 1041-1043.	1.9	2
250	199â€Baricitinib in patients with systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study. , 2019, , .		2
251	Pregnancy outcomes of a joint obstetric and rheumatology clinic in a tertiary centre: a 2-year retrospective study of 98 pregnancies. Rheumatology Advances in Practice, 2022, 6, rkac026.	0.7	2
252	Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine. Rheumatology, 0, , .	1.9	2

#	Article	IF	CITATIONS
253	Efficiency in follow-up immunology testing for patients with connective tissue diseases and vasculitis. Clinical Medicine, 2011, 11, 632-633.	1.9	1
254	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. Arthritis Research and Therapy, 2017, 19, 287.	3.5	1
255	127 Quality of life in patients with connective tissue diseases: results from the Lupus Extended Autoimmune Phenotype (LEAP) study. Rheumatology, 2018, 57, .	1.9	1
256	A molecular taxonomy for systemic autoimmune rheumatic diseases (SARDs): learning lessons from oncology?. Rheumatology, 2020, 59, 2193-2194.	1.9	1
257	O17 Effectiveness of rituximab in the treatment of neuro-psychiatric SLE: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology, 2021, 60, .	1.9	1
258	Clinical features of psoriatic arthritis. , 2011, , 1183-1193.e2.		1
259	Clinical features of psoriatic arthritis. , 2015, , 989-997.		1
260	Systemic lupus erythematosus: a pragmatic guide to current management: IP63. Assessment and Management of Systemic Lupus Erythematosus in the Routine Clinic Setting. Rheumatology, 2011, 50, iii16-iii16.	1.9	0
261	041. Anti-Citrullinated Protein Antibody Status in the General Population and as a Predictor of Future Inflammatory Polyarthritis: The Epic-2-Noar Study. Rheumatology, 2015, , .	1.9	0
262	292. Characterizing Pregnancy Vascular Changes in SLE. Rheumatology, 0, , .	1.9	0
263	O14.â€∫Vitamin D Improves Endothelial Function and Endothelial Repair in Systemic Lupus Erythematosus. Rheumatology, 2015, , .	1.9	0
264	019. Acute Necrotizing Pancreatitis in SLE: A Case Report and Literature Review. Rheumatology, 2015, , .	1.9	0
265	O10. Risk and Characteristics of Drug-Induced Lupus in Patients Exposed to Tumour Necrosis Factor-α Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology, 2015, , .	1.9	0
266	E70 A Stratified Medicine Approach to Drug Response in Systemic Lupus Erythematosus. Rheumatology, 2016, , .	1.9	0
267	Medication-related side effects in vasculitis: a patient self-report survey of awareness and reported uptake of protective therapy. Rheumatology, 2016, 55, 185-186.	1.9	0
268	319. THE EFFECTS OF DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS ON ATTENTION. Rheumatolo 2017, 56, .	999 _{1.9}	0
269	CS-07â€Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
270	126 Cross sectional validation of BILAG2004-Pregnancy Index. Rheumatology, 2018, 57, .	1.9	0

#	Article	IF	CITATIONS
271	137 Predictors of hypogammaglobulinaemia in rituximab treated systemic lupus erythematosus and vasculitis patients. Rheumatology, 2018, 57, .	1.9	0
272	O21 BILAG2004-Pregnancy index is sensitive to change. Rheumatology, 2018, 57, .	1.9	0
273	O08â€fSymptoms in first degree relatives of patients with rheumatoid arthritis: evaluation of data from the symptoms in persons at risk of rheumatoid arthritis questionnaire. Rheumatology, 2019, 58, .	1.9	0
274	233 Enhancing quality improvement capacity through the British Society for Rheumatology's multi-region audit into the management of adults with systemic lupus erythematosus. Rheumatology, 2019, 58, .	1.9	0
275	098â€∫Quality improvement to halve non-adherence to methotrexate. Rheumatology, 2019, 58, .	1.9	0
276	242 Baseline characteristics of patients with lupus nephritis requiring rituximab therapy: results from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR). Rheumatology, 2019, 58, .	1.9	0
277	, 145 The British Society for Rheumatology's Choosing Wisely UK recommendations. Rheumatology, 2019, 58, .	1.9	0
278	FRI0188â€EARLY RENAL IMPROVEMENTS FOLLOWING RITUXIMAB IN LUPUS NEPHRITIS. , 2019, , .		0
279	FRI0173â€HOW WELL DO CLINICAL TRIALS REPRESENT REAL WORLD LUPUS NEPHRITIS PATIENTS?. , 2019, , .		0
280	P175 MASTERPLANS: prediction of response to rituximab in SLE using a validated two-score system for interferon. Rheumatology, 2020, 59, .	1.9	0
281	P169â€∱A validated two-score system for interferon is a predictor of response to rituximab in SLE. Rheumatology, 2021, 60, .	1.9	0
282	P096 Pregnancy outcomes in women attending a joint obstetric and rheumatology clinic in a tertiary centre over a 2-year period. Rheumatology, 2021, 60, .	1.9	0
283	P166â€∱Multimorbidity in SLE, a barrier to clinical trial eligibility: results from the BILAG-BR. Rheumatology, 2021, 60, .	1.9	Ο
284	P170 The validity and utility of the SLE-key® rule-out serological test when applied in a selected cohort of patients with SLE and other connective tissue diseases. Rheumatology, 2021, 60, .	1.9	0
285	O19â€fEasy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004. Rheumatology, 2021, 60, .	1.9	0
286	1124â€Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach. , 2021, , .		0
287	1107â€Economic evaluation of hydroxychloroquine use in an international inception cohort. , 2021, , .		0
288	Probabilistic Approaches to Overcome Content Heterogeneity in Data Integration: A Study Case in Systematic Lupus Erythematosus. Studies in Health Technology and Informatics, 2020, 270, 387-391.	0.3	0

#	Article	IF	CITATIONS
289	P039 Septic arthritis caused by Mycoplasma hominis in a patient with systemic lupus erythematosus. Rheumatology, 2022, 61, .	1.9	0
290	P240 Predictors and prognostic factors influencing outcomes of anti-CD20 monoclonal antibodies in systemic lupus erythematosus: a systematic review update. Rheumatology, 2022, 61, .	1.9	0
291	P068 Monitoring of methotrexate blood toxicity during the COVID-19 pandemic for patients with rheumatoid arthritis: data from the Greater Manchester Care Record. Rheumatology, 2022, 61, .	1.9	Ο
292	The BILAG-2004 index is associated with development of new damage in SLE. Rheumatology, 0, , .	1.9	0